valencia nutrition has scheduled a meeting of its Board of Directors for Thursday, May 28, 2026. The meeting will be held at 12:30 p.m. IST to discuss and approve key financial agenda items.

Agenda for the Meeting

The primary purpose of the meeting is to consider and approve the Audited Standalone and Consolidated Financial Results of the Company. These results pertain to the half-year and financial year ended March 31, 2026. The approval will include the Report of the Statutory Auditor, as recommended by the Audit Committee.

Trading Window Closure

In compliance with the Company's Code of Conduct for the prevention of Insider Trading and the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of the Company will remain closed. This closure is effective from the end of the half-year and financial year ended March 31, 2026, and will continue until 48 hours after the declaration of the Audited Standalone and Consolidated Financial Results.

The restriction applies to all Directors, designated employees, connected persons, auditors, consultants, and their immediate relatives.

Key Meeting Details

Valencia Nutrition Limited has secured a significant regulatory milestone with the receipt of listing approval from BSE Limited for equity shares arising from warrant conversion. The approval, dated April 16, 2026, marks an important step in the company's capital structure enhancement.

BSE Listing Approval Details

The company received formal listing approval from BSE Limited through letter reference number LOD/PREF/SS/FIP/83/2026-27. The approval encompasses the following key parameters:

Regulatory Compliance

The intimation was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to disclose material events and information that could impact investor decisions. The warrant conversion and subsequent listing approval falls under this disclosure requirement.

Corporate Structure Impact

The conversion of warrants into equity shares represents a structured approach to capital raising through the preferential route. The warrants were initially allotted to the Promoter Category, indicating internal capital infusion to support business operations and growth initiatives.

Official Communication

The formal intimation was signed by Jay Shah, Whole-Time Director & CFO, bearing DIN 09072405. The communication was digitally signed on April 16, 2026, ensuring authenticity and regulatory compliance. The company has provided a copy of the BSE listing approval as supporting documentation for the disclosure.